Last reviewed · How we verify
Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients (ALCAP)
The investigator assesses the efficacy and safety of alpelisib and capecitabine in patients with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies.
Details
| Lead sponsor | Korean Cancer Study Group |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | UNKNOWN |
| Enrolment | 65 |
| Start date | Sun Feb 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Feb 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Metastatic Colorectal Cancer
- PIK3CA Gene Mutation
Interventions
- Alpelisib plus Capecitabine combination
Countries
South Korea